ACRF research funds critical to keeping international edge: Frazer

October 11, 2005

The Australian Cancer Research Foundation fills a "significant niche" in cancer research with its large infrastructure grants allowing Australian research groups to retain a competitive edge internationally, according to University of Queensland's Professor Ian Frazer.

Frazer, whose team grabbed worldwide headlines this week by developing a cervical cancer vaccine, previously received an ACRF grant that allowed it to leverage $2m from the Queensland Government and the University of Queensland for much-needed laboratory space on the Princess Alexandra Hospital campus.

He said that Australia was at a critical time in the area of cancer research.

"Internationally, advances in cancer biology and cancer therapy are more than ever dependent on 'big science' requiring access to expensive technology, and on networking between basic science groups, clinician scientists, and practicing clinicians in an environment where clinical research is not only permitted but positively encouraged.

"For Australia to build on its past successes and retain a place on the world stage will require ongoing commitment to funding of dedicated research facilities and to provision of staff with the appropriate training, skills, and opportunities to conduct world class research," Frazer said.

As for the future of cancer research in Australia, Frazer said that the focus was translational research underpinned by good basic research.

"Breakthroughs rarely come when they're expected, and major advances in the management of cancer don't come only from clinicians doing cancer research.

"If you can inspire bright people to tackle important issues, the improved understanding will lead eventually to practical benefits for patients," he said.

"The critical and rate-limiting step is always funding - funding to provide competitive infrastructure and adequate salaries, sufficient to attract and retain the brightest minds in research, funding so that basic science is well done even if there isn't an immediately practical application, and funding so that all patients who wish to get the opportunity to take part in well designed and well supported clinical trials," he added.
For more information, please contact Suzie Graham at ACRF on +612 9223 7833

Research Australia

Related Cancer Research Articles from Brightsurf:

As cancer has evolved, it is time for cancer research to do the same
Marking Lung Cancer Awareness month, a new study investigates the extent to which human-based, non-animal approaches are supplanting animal models in cancer research - comparing number of publications, funding, and publications associated with clinical trials between xenograft models and human organoids.

New liver cancer research targets non-cancer cells to blunt tumor growth
'Senotherapy,' a treatment that uses small molecule drugs to target ''senescent'' cells, or those cells that no longer undergo cell division, blunts liver tumor progression in animal models according to new research from a team led by Celeste Simon, PhD, a professor of Cell and Developmental Biology in the Perelman School of Medicine at the University of Pennsylvania and scientific director of the Abramson Family Cancer Research Institute.

Blueprint to beat cancer launched today by World Cancer Research Fund (WCRF)
Overweight and obesity increase cancer risk. A new report published today by World Cancer Research Fund (WCRF), and presented at the European Congress on Obesity in Vienna, shows that overweight or obesity is a cause of at least 12 cancers, five more than WCRF findings a decade ago.

Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.

UA Cancer Center research team explores anti-breast cancer properties of soy
Genistein, a major compound in soy foods, might aid in the proper functioning of a gene that can malfunction to cause breast cancer.

Hitgen and Cancer Research UK's Manchester Institute enter license agreement in lung cancer
Cancer Research UK, Cancer Research Technology (CRT), the charity's commercial arm, and HitGen Ltd, a privately held biotech company focused on early drug discovery, announced today that they have entered into a licence agreement to develop a novel class of drugs against lung cancer.

The potential consequences for cancer care and cancer research of Brexit
Cancer leaders highlight main fears for patient care, treatment and research in a post-Brexit world.

Cancer Research UK announces Grand Challenge teams to answer biggest questions in cancer
Cancer Research UK today announces that four international teams are the first recipients of its global £100 million Grand Challenge competition, which aims to overcome the biggest challenges facing cancer researchers in a global effort to beat cancer sooner.

Huntsman Cancer Institute research holds promise for personalized lung cancer treatments
New research from scientists at Huntsman Cancer Institute (HCI) at the University of Utah uncovered distinct types of tumors within small cell lung cancer that look and act differently from one another.

Leading cancer research organizations to host cancer immunotherapy conference
The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) will sponsor the second International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel (811 7th Ave., New York, NY 10019) and the New York Hilton Midtown ( 1335 Avenue of the Americas, New York, NY 10019), Sept.

Read More: Cancer Research News and Cancer Research Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to